Talquetamab: A New GPRC5D Targeted Therapy On The Horizon

HealthTree University: Therapies On The Horizon - Talquetamab

Talquetamab is a bi-specific antibody that targets a specific GPRC5D antigen on myeloma cells, offering a promising alternative approach to treating multiple myeloma. Learn about the potential benefits it brings to patients. Watch the video below for more information on how it works, its side effects, dosing, and administration. You can watch the whole Therapies on the Horizon course at HealthTree University.

Talquetamab

We’d like to thank our faculty who donated their time in creating these videos, including:

• Krina Patel, MD, MSc
• Ravi Vij, MD, MBA

Want more?

We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!

• Myeloma Basics Part 1
• Myeloma Basics Part 2
• Myeloma Basics Part 3
• Myeloma Care Basics
• Building Your Healthcare Team
• Becoming an Empowered Patient
• Starting Myeloma Treatment
• Know Your Therapy
• Know Your Labs: Blood and Urine Testing in Myeloma
• Autologous Stem Cell Transplant (ASCT)
• Precursor Conditions
• Relapsed and Refractory MM Treatment
• Classes of Drugs
• Immunotherapy
• Myeloma Bone Disease
• Imaging in Myeloma
• MRD Testing
• Basic Genetics and Cancer Biology
• Myeloma Genetics
• Types of Genetic Testing in Myeloma
• Specific Myeloma Genetics Mutations and Risk
• Precision Medicine
• Financial Advice for Myeloma Patients and Their Families
• Geriatric Care and Myeloma
• Myeloma Kidney Disease
• Amyloidosis
• Myeloma Basics (Spanish)
• COVID-19 and Multiple Myeloma
• Complementary and Integrated Therapy
• Allogeneic Stem Cell Transplant
• Survivorship
• Clinical Trials
• Understanding Basic Blood Tests
• Myeloma Vaccines